← All trials
NCT04204252
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2019
- Primary completion
- Nov 30, 2022
- Completion date
- May 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kamada, Ltd.Lead sponsor
- Leiden UniversityOverall official - principal investigator
- Syneos HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.